Kymera Therapeutics (KYMR) Equity Ratio (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Equity Ratio data on file, last reported at 0.92 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.92, up 7.74% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.92 (up 7.74% YoY), and the FY2025 annual result was 0.91, up 6.09% from the prior year.
• Equity Ratio improved to 0.92 in Q1 2026 per KYMR's latest filing, from 0.91 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.92 in Q1 2026 and troughed at 0.69 in Q4 2023.
• A 5-year average of 0.81 and a median of 0.82 in 2024 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2022 and 2023: Equity Ratio advanced 28.51% in 2022, then decreased 15.59% in 2023.
• A 5-year view of Equity Ratio shows it stood at 0.81 in 2022, then declined by 15.59% to 0.69 in 2023, then advanced by 24.55% to 0.85 in 2024, then climbed by 6.09% to 0.91 in 2025, then climbed by 1.78% to 0.92 in 2026.
• Business Quant data shows KYMR's Equity Ratio at 0.92 in Q1 2026, 0.91 in Q4 2025, and 0.86 in Q3 2025.